Diberdayakan oleh Blogger.

Popular Posts Today

BATS Global Markets buying Direct Edge

Written By Unknown on Selasa, 27 Agustus 2013 | 00.33

NEW YORK — Securities exchange operator BATS Global Markets Inc. is buying Direct Edge LLC.

Financial terms were not disclosed Monday.

The four U.S. equity exchanges run by BATS and Direct Edge will remain in operation. These include the BATS BZX and BYX Exchanges and the Direct Edge EDGX and EDGA Exchanges.

The combined company will use the proprietary BATS technology. It will be headquartered in Kansas City, Mo., where BATS is based.

BATS CEO Joe Ratterman will serve as CEO of the combined company. Direct Edge CEO William O'Brien will serve as president.

The transaction is expected to close in the first half of next year.


00.33 | 0 komentar | Read More

As ESPN looks to stay on top, challenges are clear

BRISTOL, Conn. — It's altogether fitting that the first event at ESPN's colossal Digital Center 2 looked to the future as the company faces more than the usual challenges.

DC2 is still mostly a shell, at least seven months from opening as the new home of "SportsCenter" and other shows. But last week, ESPN executives, anchors and top producers invited 40 reporters into the main studio space for a look at what the technology marvel will mean to the sports media giant — starting with an animated video showing that very room in full use.

Nothing odd there. Famously, ESPN has grasped the future aggressively since it launched in 1979 in a half-finished studio a few hundred yards away.

Changes are all the more intense these days, as the Walt Disney Co. subsidiary brings on some high-profile personalities, including its controversial former anchor Keith Olbermann; launches the SEC Network to showcase college football's dominant conference with a just-announced schedule for 2014; and fills DC2, whose $150 million price tag the company won't confirm, with electronic wizardry of the sort we've only seen in sci-fi and the National Security Agency until now.

But there are two ways of looking at the picture. The first is that ESPN is unstoppable, with 4,000 employees in a hometown that company president John Skipper spoke about in romantic terms. This collection of networks and websites is the undisputed champion of sports content at a time when content reigns in the screwy world of closed capitalism we call cable TV — where sports, as Skipper said, is the only way to bring the nation together.

The other view has the sprawling ESPN in a powerful but vulnerable position. A round of layoffs this summer reminded ESPN that it's a brutal world out there, and even a business that commands a reported $5.50 a month from each of 98 million households that get the flagship network has its limits. Going after that endless gold, Fox just launched the Fox Sports 1 network in direct competition with ESPN.

Moreover, as a new generation of fans comes of age with less TV and more digital devices, ESPN's business model could face disruption by losing some of that coerced cable money, by seeing new competition from the likes of Google, or even by missing a wave — though for now, ESPN is well-positioned digitally.

Finally, as ESPN looks to expand globally, it's finding that a narrower landscape — soccer and more soccer — is harder to dominate than ESPN had imagined.

'HAPPY FOR THEM'

Skipper is the picture of steady-handed confidence in all this, a tall Southerner with updated charm that includes hip glasses; calm, but willing to show some swagger. When a journalist asked him to react to the reported 23 cents per household that the fledgling Fox Sports 1 channel commands — a disappointing figure that Fox reportedly hoped would rise sharply before its launch — Skipper put on a smile.

"I'm happy for them."

Locker room posting alert! Red Auerbach would have cringed if one of his Boston Celtics said something like that about a Lakers misfortune. And now, somewhere in a Fox studio, Skipper's comment lives on a bulletin board.

That's fine with Skipper, fine with ESPN's culture. "We like competition. It's always a way to make us better," he said.

But he added, "Our goal is to have the best competition for ESPN come from ESPN."

Enter Olbermann, whose 11 p.m. show on ESPN2 will launch Monday night. Olbermann exited ESPN as a star anchor 16 years ago with harsh words for the network and for Bristol, which he called "godforsaken." So, no, he won't return to the city of mums for his show, which will originate in New York.

Skipper, who spoke in a conference room, not in DC2, said in a response to my question that when he personally courted Olbermann, he never even raised the notion of a return to Bristol for the sharp-tongued political commentator.

Speaking of politics — the third rail of American sports — that's out for Olbermann.

"He wants to do a sports show, we'll let him do a sports show," Skipper said. "When sports does bump up against other things, we're OK with that. ... But we're not covering gun legislation and he's not veering off into politics."

We'll see about muzzling Olbermann. Speaking of competition, Olbermann's show will bump up against Jon Stewart's "The Daily Show," not to mention one of ESPN's most popular "SportsCenter" slots. Skipper said that Olbermann does for sports what Stewart does for news, but that he didn't think the two shows would take many viewers from each other. Again, we'll see about that.

ESPN is punching up its Los Angeles and New York studios, but as for Bristol, Skipper was surprisingly effusive.

"It's a big part of the culture. You kind of have to get Bristol to understand ESPN," said Skipper, who joined ESPN in 1997 at the magazine. "It really does ground people. … This is working class, salt-of-the-Earth America, and we're proud to be here."

That's reassuring for us in central Connecticut, all the more since the recent layoffs, a rarity for ESPN, didn't hit Bristol especially hard. About 125 people in the hometown were let go out of a worldwide job cut of more than 300, which included the elimination of some unfilled positions. Skipper portrayed it as "a significant look at how we manage our people and resources." That means the company stopped doing a few things, including 3D TV, Skipper said.

But any broad layoff is also about pushing efficiency, and that's a scary idea if you think about it as a recurring exercise, as it is at so many firms. As Skipper spoke, word emerged of 175 layoffs at ESPN's sister Disney company, ABC.

Skipper, once again, was a calming voice. "It was the least fun thing I've had to do in this job," he said. "It was very difficult culturally at this company. It is not something we will get used to doing."

In fact, he said, ESPN will remain a growth company, easily meeting the targets it set to add 200 local jobs between 2011 and 2016. "We will shortly have more employees than we have ever had," he said.

WHO'S THE STAR?

The highest-profile ESPN staffers, the anchors, are surprisingly numerous — 42 of them appear on the nearly around-the-clock "SportsCenter" shows. And with the technology enabled by the new Digital Center 2, ESPN intends to let those anchors punch up their on-air personalities.

For highlights, "We will have the ability to not always go to a full-screen, to incorporate the anchor into the show more," said Mark Gross, senior vice president and executive producer.

Looking further ahead, ESPN is already the leader in live sports events online at its ESPN3 network. But Google, Apple and others could look to compete directly in that space. Skipper, again the calming influence (the pattern is clear) doesn't see a major shift in viewer habits. He says this is the one and only "golden age of television," and that the much-ballyhooed migration from cable is driven by incomes and economics, not lifestyles.

"Almost everyone who has cut the cord would like to re-establish the cord if they could afford it," he said.

Still, even a modest rise in direct online events gives ESPN yet another front to cover.

One illustration of ESPN's immense reach and the challenges that come with it happened Thursday, when ESPN ended its involvement with the PBS "Frontline" show about the NFL's handling of players' head injuries. ESPN said it made the move because it didn't have enough editorial control over the project, which is set to air in October. The New York Times reported that the NFL pressured ESPN to pull out, a charge the league and the media company both deny.

Skipper had said the day before that ESPN prides itself on working with sports leagues as partners while also covering them as journalists.

Whatever the reason for ESPN's move, it highlights the sensitive position created by the company's ubiquitous involvement in sports media.

All of it, together, raises a question about focus. Here we have a media company with six main TV networks, an online network and a universe of web pages, a magazine, a radio network, a studio full of big personalities who cover huge stars, working for a media business whose technology has star power itself. In addition to Olbermann, ESPN has snagged analytic blogger extraordinaire Nate Silver from The New York Times, who will enjoy a lot of freedom.

Is there not a danger, I asked the ESPN panel, that the ship gets too unwieldy with too much star power?

"At the end of the day it's still about the content that we produce," Gross said. "The beauty of this place, it's high-volume, high-octane. We take a bunch of risks; some work out, some don't. It's all about the content. That's how we prioritize."

Rob King, the senior vice president overseeing digital content, added, "We focus on fans."

And for "SportsCenter" anchor Steve Levy, challenges such as Fox Sports 1 are great for focus. "If you've seen me the last three nights I was absolutely pumped up," he said. "A lot of us got into my end of the business because we can't play sports, but that doesn't mean we're not competitive."

He's on the 11 p.m. show. "As far as I'm concerned, that's the biggest show in the building. ... I'd like to stay right where I am and keep going."

For him, and for the most valuable media brand in the world, the position is enviable, and the challenge is clear.

———

©2013 The Hartford Courant (Hartford, Conn.) Distributed by MCT Information Services

Visit The Hartford Courant (Hartford, Conn.) at www.courant.com


00.33 | 0 komentar | Read More

Deals send stocks edging higher on Wall Street

NEW YORK  — A handful of corporate deals helped nudge the stock market higher despite a disappointing report on the economy.

Amgen surged after the biotech giant said it plans to buy Onyx Pharmaceuticals for $10.4 billion. The deal would give Amgen three approved cancer treatments and several others in clinical trials.

The Standard & Poor's 500 index rose four points, or 0.3 percent, to 1,667 as of noon Monday.

The Dow Jones industrial average rose 24 points, or 0.2 percent, to 15,034. The Nasdaq composite rose 21 points, or 0.6 percent, at 3,679.

Orders for long-lasting manufactured goods plunged 7.3 percent last month, the steepest drop in nearly a year.

Amgen gained $9.64, or 9 percent, to $115.29. Onyx rose $6.62, or 6 percent, to $123.58.


00.33 | 0 komentar | Read More

Mass. gas prices down 2 cents per gallon

BOSTON — Gasoline prices in Massachusetts continue their downward trend, falling another 2 cents per gallon the past week.

AAA Southern New England reports Monday that a gallon of self-serve, regular has dropped to an average of $3.62.

That's 11 cents lower than at the same time last year, but still 8 cents higher than the current national average.

AAA found self-serve, regular selling as low as $3.46 per gallon and as high as $3.99.


00.33 | 0 komentar | Read More

Probe doesn't find fraud at BP spill claims office

NEW ORLEANS — The head of security for the administrator of BP's multibillion-dollar settlement with Gulf Coast residents and businesses says an internal probe of alleged misconduct by an employee of a Mobile, Ala., claims center hasn't turned up any evidence of fraud.

BP said it received a tip in July that someone who worked at the Mobile office helped people submit fraudulent claims in exchange for some of the settlement money.

But David Welker, a former FBI supervisor who now works for claims administrator Patrick Juneau, says in a letter last week that his investigation found no evidence of fraud in any of the claims handled by the employee.

BP cited the employee's alleged misconduct in its Aug. 5 request for a federal judge to temporarily suspend all settlement payments.


00.33 | 0 komentar | Read More

Grain futures higher on the CBOT

CHICAGO — Grains futures were mostly higher Monday in early trading on the Chicago Board of Trade.

Wheat for December delivery was unchanged at 6.3450 a bushel; December corn was 22.50 cents higher at $4.9250 a bushel; December oats were unchanged at $3.63 a bushel; while November soybeans were 60 cents higher at 13.88 a bushel.

Beef prices were mostly higher while pork prices were higher on the Chicago Mercantile Exchange.

October live cattle was .70 cent higher at $1.2740 a pound; October feeder cattle was .45 cent lower at $1.5840 a pound; October lean hogs was .72 higher at $.8582 a pound.


00.33 | 0 komentar | Read More

Bay State building permits skyrocket in July

The number of permits for new, privately owned housing units in Massachusetts soared in July, according to new census data.

Last month, building permits for 1,880 units were authorized, compared to 1,724 in June and 715 in July 2012.

The total number of new units so far this year in the state was 8,991, compared to 5,633 over the same period last year.

Nationally, permits for 88,145 units were authorized last month, compared to 83,925 in June and 72,056 in July 2012.


00.33 | 0 komentar | Read More

Internal probe: No fraud at BP claims center in AL

NEW ORLEANS — The head of security for the administrator of BP's multibillion-dollar settlement with Gulf Coast residents and businesses says an internal probe of alleged misconduct by an employee of a Mobile, Ala., claims center hasn't turned up any evidence of fraud.

BP said it received a tip in July that someone who worked at the Mobile office helped people submit fraudulent claims in exchange for some of the settlement money.

But David Welker, a former FBI supervisor who now works for court-supervised claims administrator Patrick Juneau, said in a letter dated Aug. 22 that his investigation found no evidence of fraud in any of the claims handled by the employee.

BP cited the employee's alleged misconduct in its Aug. 5 request for a federal judge to temporarily suspend all settlement payments. U.S. District Judge Carl Barbier rejected a similar request by BP in July, but he hasn't ruled yet on the company's renewed bid to suspend payments.

In a court filing Sunday, two of the plaintiffs' attorneys who brokered the settlement with BP said the company hasn't presented any evidence that any claim was improperly calculated or paid.

"There is not even an argument, much less an evidentiary showing, to support the injunction of the entire Settlement Program," wrote the lawyers, Stephen Herman and James Roy.

In his letter to a BP official, Welker said the Mobile employee accused of misconduct has helped 124 people. All of those claims were placed on hold.

The employee's mother filed a claim, but she denied any wrongdoing and withdrew it, Welker said.

"We have found no evidence to support the allegation of fraud pertaining to any of these claims," Welker wrote. "In fact, we have learned that (the employee) referred 32 of these claimants for fraud review by the (settlement program), leading to the detection of a significant multi-claimant scheme."

In July, Juneau suspended the Mobile employee and another accused of accessing claims data for that person. Welker said a subsequent examination of the employees' computers and emails revealed no evidence of fraud.

BP also has said it recently discovered that two lawyers who have served as "appeals panelists" for the settlement program apparently had conflicts of interest. The lawyers, who have ruled on appeals of disputed settlement awards, were partners at law firms that have represented claimants and filed claims of their own to be compensated.

Herman and Roy, the plaintiffs' attorneys, said the appeals panelists are supervised by the court, not Juneau.

"The notion that the Claims Administrator had an obligation or failed to 'police' the Appeals Panelists is absurd," they wrote.

On July 2, Barbier appointed former FBI Director Louis Freeh to conduct an independent investigation of the settlement program, including possible misconduct by a lawyer who worked on Juneau's staff.

Lionel H. Sutton III is accused of receiving a portion of settlement proceeds for claims he referred to a law firm before he went to work for Juneau. Sutton, who resigned from Juneau's staff on June 21, has denied the allegations.


00.33 | 0 komentar | Read More

Deals send stocks edging higher on Wall Street

NEW YORK — A handful of corporate deals helped nudge the stock market up in midday trading Monday, despite a disappointing report on the economy.

Amgen surged 8 percent, the biggest gain in the Standard & Poor's 500 index, after the biotech giant said it plans to buy Onyx Pharmaceuticals for $10.4 billion. The merger, announced late Sunday, would give Amgen three approved cancer treatments and several others in clinical trials.

The S&P 500 index was up three points, or 0.2 percent, to 1,666 as of 12:30 p.m. EDT. Health-care companies led seven of the 10 industry sectors in the S&P 500 slightly higher.

The Dow Jones industrial average rose 24 points, or 0.2 percent, to 15,035. The Nasdaq composite index rose 19 points, or 0.5 percent, at 3,667.

In economic news, the government reported that orders for long-lasting manufactured goods plunged 7.3 percent last month, the steepest drop in nearly a year. Demand for commercial aircraft sank and businesses spent less on computers and electrical equipment.

Jack Ablin, the chief investment officer at BMO Private Bank in Chicago, said it's likely that investors are looking past the one bad economic report because so many major events loom ahead.

The Federal Reserve will start a two-day meeting Sept. 17 at which officials will discuss easing support for the economy. After that, Germany holds national elections that could change how the region handles rescue loans for troubled countries. Congress returns from vacation next week and will have to take up a new budget before the fiscal year starts on Oct. 1.

"These issues are big enough to transcend daily data," Ablin said.

It's also expected to be a quiet week, because volume usually dries up in the last weeks of August. Trading desks are thinly staffed, as Labor Day marks the end of Wall Street's summer vacation.

News that members of the Pritzker family have agreed to buy TMS International sent the company's stock up 12 percent. The deal values the service provider to steel mills at roughly $1 billion. The Pritzker family, one of America's wealthiest, operates a global industrial conglomerate and founded the Hyatt hotel chain. TMS jumped $1.81 to $17.38.

With five trading days left in August, the major indexes are on track to end the month with slight losses. The Dow is down 3 percent for the month and the S&P 500 is down 1 percent.

In the market for U.S. government bonds, the yield on the 10-year note slipped to 2.79 percent from 2.82 percent late Friday. That followed an even sharper decline on Friday, when the declined seven basis points.

Crude oil slipped 56 cents to $105.86 a barrel and gold fell $1.80 to $1,394 an ounce.

Among other stocks making big moves:

— Anadarko Petroleum climbed $1.74, or 2 percent, to $91.54. The oil and gas producer said late Sunday that it's selling part of its stake in a natural-gas site off the shores of Mozambique for $2.64 billion.

— Amgen gained $9.50 to $115.05, hitting a new all-time high. Onyx rose $6.72, or 6 percent, to $123.68.

— The electric-car maker Tesla climbed $9.69, or 6 percent, to $171.50, following reports that, in California, Tesla's Model S outsold Cadillac, Porsche, Jaguar and other brands in June.


00.33 | 0 komentar | Read More

Clarification: Amgen-Onyx story

NEW YORK — In a story Aug. 25, The Associated Press reported that Onyx Pharmaceuticals and Pfizer Inc. are studying a potential breast cancer treatment, called palbociclib, and oprozomib, a potential multiple myeloma drug that is in early clinical testing.

In fact, Pfizer is conducting the palbociclib studies. Onyx could receive payments based on the drug's approval and sales.

Onyx is developing oprozomib. Pfizer is not involved with that potential treatment.

An updated version of the story is below:

Amgen buying cancer drug maker Onyx for $10.4B

Amgen agrees to buy cancer drug maker Onyx for $10.4B, or $125 per share

NEW YORK (AP) — Biotech drugmaker Amgen will buy cancer drug maker Onyx Pharmaceuticals for about $10.4 billion in cash in a deal that will add several cancer drugs to Amgen's stable and boost its pipeline of new drugs.

Amgen Inc. said Sunday that it will acquire Onyx for $125 per share, and it expects to complete the deal at the beginning of the fourth quarter. The companies value the deal at $9.7 billion excluding Onyx's cash, and Amgen said it will use $8.1 billion in committed bank loans to finance the deal.

Onyx rejected an offer from Amgen worth $120 per share in June.

Amgen is the biggest biotech drug company in the world. Its products include Prolia for osteoporosis, Enbrel for rheumatoid arthritis and skin disorders, and Neulasta and Neupogen for fighting infection in cancer patients. The Thousand Oaks, Calif., company reported $17.27 billion in revenue in 2012. It said Onyx will start adding to its adjusted net income in 2015.

Onyx Pharmaceuticals Inc. makes two cancer drugs through a partnership with Bayer AG. Sales of Nexavar, a pill that is approved to treat liver and kidney cancer, totaled $861 million in 2012. Onyx received $288 million in revenue from those sales. Stivarga was approved in September as a treatment for colorectal cancer, and won additional approval in February for use against tumors of the intestinal tract that did not respond to other treatments. Onyx and Bayer also are testing Nexavar as a treatment for breast cancer. And Onyx could receive milestone payments and royalties from palbociclib, a drug that Pfizer Inc. is studying as a breast cancer treatment.

In July the FDA approved Onyx's Kyprolis as a treatment for multiple myeloma, a type of blood cancer. Multiple myeloma causes tumors to grow in the bone marrow, preventing the production of normal blood cells. The FDA approved Kyprolis for patients who have already been treated with at least two other multiple myeloma drugs, and Onyx is conducting other trials to win broader marketing approval. Onyx also is developing oprozomib, a potential multiple myeloma drug that is in early clinical testing.

The new offer comes at a 44 percent premium to Onyx's closing price on June 28, before reports of Amgen's initial bid. In the days after Amgen's first offer was made public, shares of the South San Francisco company climbed as high as $136.87. The stock closed at $116.96 Friday.

The Onyx drugs would add to Amgen's pipeline of new medicines. In the first half of 2014 Amgen expects to announce late-stage testing data for three experimental drugs. The products are being studied as treatments for skin cancer, recurrent ovarian cancer and high LDL, or bad cholesterol, that doesn't respond to pills such as Lipitor.

The deal continues a wave of several other major pharmaceutical acquisitions that have been announced in the last few months. In July, generic drug maker Perrigo Co. agreed to buy Ireland's Elan Corp. PLC for $8.6 billion. That deal will allow Perrigo to move to Ireland and cut its tax obligations while adding new royalties. In May generic drug company Actavis Inc. agreed to buy Warner Chilcott PLC for $8.5 billion in stock, creating the third-biggest specialty pharmaceutical company in the U.S. market.

Also in May, Valeant Pharmaceuticals International Inc. agreed to pay $8.7 billion to buy Bausch + Lomb in a massive expansion of Valeant's ophthalmology business. In April scientific instrument maker Thermo Fisher Scientific Inc. agreed to buy life science and medical research instrument maker Life Technologies Corp. for $13.6 billion.


00.33 | 0 komentar | Read More
techieblogger.com Techie Blogger Techie Blogger